Rybelsus for PCOS: Evidence, Eligibility, Coverage
Rybelsus is not FDA approved for polycystic ovary syndrome (PCOS). It is approved for type 2 diabetes and heart risk. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.
- Active ingredient
- semaglutide
- How it is taken
- daily tablet
- Approved for
- Type 2 diabetes and heart risk
- Best result (STEP 1)
- 14.9% weight loss
Rybelsus overview
Its half-life is about 1 week: after 7 d, half is gone, and after five half-lives (35 d), about 3% remains.
In PIONEER 1, people with type 2 diabetes lost 3.7 kg over 26 weeks, compared with 1.4 kg on placebo.
Monthly prices in US dollars include the list price and self-pay offers. Each price comes from the maker's price page.
Sources: FDA label (DailyMed), healthsystemtracker.org, Novo Nordisk pricing, Novo Nordisk.
Who qualifies?
| Who sets the rule | Who qualifies |
|---|---|
| FDA label | It lowers blood sugar in adults with type 2 diabetes when used with diet and exercise. |
| FDA label | It lowers the chance of a heart attack, stroke, or heart-related death for adults with type 2 diabetes at high risk. |
| Typical commercial plan (Aetna policy) | BMI 30 or higher |
| Typical commercial plan (Aetna policy) | BMI 27 or higher with a weight-related condition |
| Typical commercial plan (Aetna policy) | a 6-month program of diet and activity comes first |
This comes from the FDA DailyMed label and aetna.com.
Trial results for PCOS
No trial enrolled only people with polycystic ovary syndrome (PCOS). All participants were adults with obesity or overweight, and none had diabetes.
| Trial | Medicine | Who took part | Length | People | Main result | Comparison |
|---|---|---|---|---|---|---|
| STEP 1 |  Wegovy | Adults with obesity or overweight, without diabetes | 68 weeks | 1,961 | 14.9% weight loss | 2.4% on placebo |
| OASIS 4 | Wegovy | Adults with obesity or overweight, without diabetes | 64 weeks | 307 | 13.6% weight loss | 2.4% on placebo |
Trial source: STEP 1 (FDA label (DailyMed)).
What is different for PCOS?
| What changes | What the label says |
|---|---|
| Insulin Secretagogues or Insulin Used Together: Hypoglycemia | Low blood sugar is more likely when you take it with insulin or a sulfonylurea. Those medicines may need lower doses. |
Label information from the FDA DailyMed label.
Label warnings come from the FDA DailyMed label.
Coverage for PCOS
A GLP-1 used only for weight loss is not covered by Medicare Part D.
If your state covers weight-loss GLP-1s through Medicaid, prior authorization is normally required.
Sources: humana.com, KFF.
Alternatives for PCOS
| Medicine | For PCOS | How it is taken | Trial result |
|---|---|---|---|
| Rybelsus | Not a listed use | daily tablet | Not listed |
 Ozempic | Not a listed use | weekly injection | Not listed |
| Wegovy | Not a listed use | weekly injection or daily tablet | 14.9% weight loss |
 Mounjaro | Not a listed use | weekly injection | Not listed |
 Zepbound | Not a listed use | weekly injection | 20.9% weight loss |
 Foundayo | Not a listed use | daily tablet | 11.1% weight loss |
 Trulicity | Not a listed use | weekly injection | Not listed |
 Saxenda | Not a listed use | daily injection | 7.4% weight loss |
 Victoza | Not a listed use | daily injection | Not listed |
| Byetta | Not a listed use | twice-daily injection | Not listed |
Sources listed: the FDA label (DailyMed).
Questions to ask your prescriber
- Will this affect my birth control at all?
- When should I stop taking this before I try to become pregnant?
- Is my plan likely to cover it if PCOS is the main reason?
For complete details, read the Rybelsus prescribing information on DailyMed.